div class=ts-pagebuttonPage 1button div class=ts-image amp-img class=ts-thumb alt=Page 1: · SOC IECAS evolocumab E o 232 632 283 OLE 234 116 624 232 OLE 440 438 212 OLE 153 434 213 -10 -20 -30 -50 -60 -70 _80 Number ofsubjects: 239 120 643 Baseline 148 420 208 OLE src=https:reader034vdocumentsnetreader034viewer20220421205e99f1c14672c770645f32dfhtml5thumbnails1jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 2button div class=ts-image amp-img class=ts-thumb alt=Page 2: · SOC IECAS evolocumab E o 232 632 283 OLE 234 116 624 232 OLE 440 438 212 OLE 153 434 213 -10 -20 -30 -50 -60 -70 _80 Number ofsubjects: 239 120 643 Baseline 148 420 208 OLE src=https:reader034vdocumentsnetreader034viewer20220421205e99f1c14672c770645f32dfhtml5thumbnails2jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 3button div class=ts-image amp-img class=ts-thumb alt=Page 3: · SOC IECAS evolocumab E o 232 632 283 OLE 234 116 624 232 OLE 440 438 212 OLE 153 434 213 -10 -20 -30 -50 -60 -70 _80 Number ofsubjects: 239 120 643 Baseline 148 420 208 OLE src=https:reader034vdocumentsnetreader034viewer20220421205e99f1c14672c770645f32dfhtml5thumbnails3jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 4button div class=ts-image amp-img class=ts-thumb alt=Page 4: · SOC IECAS evolocumab E o 232 632 283 OLE 234 116 624 232 OLE 440 438 212 OLE 153 434 213 -10 -20 -30 -50 -60 -70 _80 Number ofsubjects: 239 120 643 Baseline 148 420 208 OLE src=https:reader034vdocumentsnetreader034viewer20220421205e99f1c14672c770645f32dfhtml5thumbnails4jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 5button div class=ts-image amp-img class=ts-thumb alt=Page 5: · SOC IECAS evolocumab E o 232 632 283 OLE 234 116 624 232 OLE 440 438 212 OLE 153 434 213 -10 -20 -30 -50 -60 -70 _80 Number ofsubjects: 239 120 643 Baseline 148 420 208 OLE src=https:reader034vdocumentsnetreader034viewer20220421205e99f1c14672c770645f32dfhtml5thumbnails5jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 6button div class=ts-image amp-img class=ts-thumb alt=Page 6: · SOC IECAS evolocumab E o 232 632 283 OLE 234 116 624 232 OLE 440 438 212 OLE 153 434 213 -10 -20 -30 -50 -60 -70 _80 Number ofsubjects: 239 120 643 Baseline 148 420 208 OLE src=https:reader034vdocumentsnetreader034viewer20220421205e99f1c14672c770645f32dfhtml5thumbnails6jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 7button div class=ts-image amp-img class=ts-thumb alt=Page 7: · SOC IECAS evolocumab E o 232 632 283 OLE 234 116 624 232 OLE 440 438 212 OLE 153 434 213 -10 -20 -30 -50 -60 -70 _80 Number ofsubjects: 239 120 643 Baseline 148 420 208 OLE src=https:reader034vdocumentsnetreader034viewer20220421205e99f1c14672c770645f32dfhtml5thumbnails7jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 8button div class=ts-image amp-img class=ts-thumb alt=Page 8: · SOC IECAS evolocumab E o 232 632 283 OLE 234 116 624 232 OLE 440 438 212 OLE 153 434 213 -10 -20 -30 -50 -60 -70 _80 Number ofsubjects: 239 120 643 Baseline 148 420 208 OLE src=https:reader034vdocumentsnetreader034viewer20220421205e99f1c14672c770645f32dfhtml5thumbnails8jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 9button div class=ts-image amp-img class=ts-thumb alt=Page 9: · SOC IECAS evolocumab E o 232 632 283 OLE 234 116 624 232 OLE 440 438 212 OLE 153 434 213 -10 -20 -30 -50 -60 -70 _80 Number ofsubjects: 239 120 643 Baseline 148 420 208 OLE src=https:reader034vdocumentsnetreader034viewer20220421205e99f1c14672c770645f32dfhtml5thumbnails9jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 10button div class=ts-image amp-img class=ts-thumb alt=Page 10: · SOC IECAS evolocumab E o 232 632 283 OLE 234 116 624 232 OLE 440 438 212 OLE 153 434 213 -10 -20 -30 -50 -60 -70 _80 Number ofsubjects: 239 120 643 Baseline 148 420 208 OLE src=https:reader034vdocumentsnetreader034viewer20220421205e99f1c14672c770645f32dfhtml5thumbnails10jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 11button div class=ts-image amp-img class=ts-thumb alt=Page 11: · SOC IECAS evolocumab E o 232 632 283 OLE 234 116 624 232 OLE 440 438 212 OLE 153 434 213 -10 -20 -30 -50 -60 -70 _80 Number ofsubjects: 239 120 643 Baseline 148 420 208 OLE src=https:reader034vdocumentsnetreader034viewer20220421205e99f1c14672c770645f32dfhtml5thumbnails11jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 12button div class=ts-image amp-img class=ts-thumb alt=Page 12: · SOC IECAS evolocumab E o 232 632 283 OLE 234 116 624 232 OLE 440 438 212 OLE 153 434 213 -10 -20 -30 -50 -60 -70 _80 Number ofsubjects: 239 120 643 Baseline 148 420 208 OLE src=https:reader034vdocumentsnetreader034viewer20220421205e99f1c14672c770645f32dfhtml5thumbnails12jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 13button div class=ts-image amp-img class=ts-thumb alt=Page 13: · SOC IECAS evolocumab E o 232 632 283 OLE 234 116 624 232 OLE 440 438 212 OLE 153 434 213 -10 -20 -30 -50 -60 -70 _80 Number ofsubjects: 239 120 643 Baseline 148 420 208 OLE src=https:reader034vdocumentsnetreader034viewer20220421205e99f1c14672c770645f32dfhtml5thumbnails13jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 14button div class=ts-image amp-img class=ts-thumb alt=Page 14: · SOC IECAS evolocumab E o 232 632 283 OLE 234 116 624 232 OLE 440 438 212 OLE 153 434 213 -10 -20 -30 -50 -60 -70 _80 Number ofsubjects: 239 120 643 Baseline 148 420 208 OLE src=https:reader034vdocumentsnetreader034viewer20220421205e99f1c14672c770645f32dfhtml5thumbnails14jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 15button div class=ts-image amp-img class=ts-thumb alt=Page 15: · SOC IECAS evolocumab E o 232 632 283 OLE 234 116 624 232 OLE 440 438 212 OLE 153 434 213 -10 -20 -30 -50 -60 -70 _80 Number ofsubjects: 239 120 643 Baseline 148 420 208 OLE src=https:reader034vdocumentsnetreader034viewer20220421205e99f1c14672c770645f32dfhtml5thumbnails15jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 16button div class=ts-image amp-img class=ts-thumb alt=Page 16: · SOC IECAS evolocumab E o 232 632 283 OLE 234 116 624 232 OLE 440 438 212 OLE 153 434 213 -10 -20 -30 -50 -60 -70 _80 Number ofsubjects: 239 120 643 Baseline 148 420 208 OLE src=https:reader034vdocumentsnetreader034viewer20220421205e99f1c14672c770645f32dfhtml5thumbnails16jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 17button div class=ts-image amp-img class=ts-thumb alt=Page 17: · SOC IECAS evolocumab E o 232 632 283 OLE 234 116 624 232 OLE 440 438 212 OLE 153 434 213 -10 -20 -30 -50 -60 -70 _80 Number ofsubjects: 239 120 643 Baseline 148 420 208 OLE src=https:reader034vdocumentsnetreader034viewer20220421205e99f1c14672c770645f32dfhtml5thumbnails17jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 18button div class=ts-image amp-img class=ts-thumb alt=Page 18: · SOC IECAS evolocumab E o 232 632 283 OLE 234 116 624 232 OLE 440 438 212 OLE 153 434 213 -10 -20 -30 -50 -60 -70 _80 Number ofsubjects: 239 120 643 Baseline 148 420 208 OLE src=https:reader034vdocumentsnetreader034viewer20220421205e99f1c14672c770645f32dfhtml5thumbnails18jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 19button div class=ts-image amp-img class=ts-thumb alt=Page 19: · SOC IECAS evolocumab E o 232 632 283 OLE 234 116 624 232 OLE 440 438 212 OLE 153 434 213 -10 -20 -30 -50 -60 -70 _80 Number ofsubjects: 239 120 643 Baseline 148 420 208 OLE src=https:reader034vdocumentsnetreader034viewer20220421205e99f1c14672c770645f32dfhtml5thumbnails19jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 20button div class=ts-image amp-img class=ts-thumb alt=Page 20: · SOC IECAS evolocumab E o 232 632 283 OLE 234 116 624 232 OLE 440 438 212 OLE 153 434 213 -10 -20 -30 -50 -60 -70 _80 Number ofsubjects: 239 120 643 Baseline 148 420 208 OLE src=https:reader034vdocumentsnetreader034viewer20220421205e99f1c14672c770645f32dfhtml5thumbnails20jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 21button div class=ts-image amp-img class=ts-thumb alt=Page 21: · SOC IECAS evolocumab E o 232 632 283 OLE 234 116 624 232 OLE 440 438 212 OLE 153 434 213 -10 -20 -30 -50 -60 -70 _80 Number ofsubjects: 239 120 643 Baseline 148 420 208 OLE src=https:reader034vdocumentsnetreader034viewer20220421205e99f1c14672c770645f32dfhtml5thumbnails21jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 22button div class=ts-image amp-img class=ts-thumb alt=Page 22: · SOC IECAS evolocumab E o 232 632 283 OLE 234 116 624 232 OLE 440 438 212 OLE 153 434 213 -10 -20 -30 -50 -60 -70 _80 Number ofsubjects: 239 120 643 Baseline 148 420 208 OLE src=https:reader034vdocumentsnetreader034viewer20220421205e99f1c14672c770645f32dfhtml5thumbnails22jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 23button div class=ts-image amp-img class=ts-thumb alt=Page 23: · SOC IECAS evolocumab E o 232 632 283 OLE 234 116 624 232 OLE 440 438 212 OLE 153 434 213 -10 -20 -30 -50 -60 -70 _80 Number ofsubjects: 239 120 643 Baseline 148 420 208 OLE src=https:reader034vdocumentsnetreader034viewer20220421205e99f1c14672c770645f32dfhtml5thumbnails23jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 24button div class=ts-image amp-img class=ts-thumb alt=Page 24: · SOC IECAS evolocumab E o 232 632 283 OLE 234 116 624 232 OLE 440 438 212 OLE 153 434 213 -10 -20 -30 -50 -60 -70 _80 Number ofsubjects: 239 120 643 Baseline 148 420 208 OLE src=https:reader034vdocumentsnetreader034viewer20220421205e99f1c14672c770645f32dfhtml5thumbnails24jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 25button div class=ts-image amp-img class=ts-thumb alt=Page 25: · SOC IECAS evolocumab E o 232 632 283 OLE 234 116 624 232 OLE 440 438 212 OLE 153 434 213 -10 -20 -30 -50 -60 -70 _80 Number ofsubjects: 239 120 643 Baseline 148 420 208 OLE src=https:reader034vdocumentsnetreader034viewer20220421205e99f1c14672c770645f32dfhtml5thumbnails25jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 26button div class=ts-image amp-img class=ts-thumb alt=Page 26: · SOC IECAS evolocumab E o 232 632 283 OLE 234 116 624 232 OLE 440 438 212 OLE 153 434 213 -10 -20 -30 -50 -60 -70 _80 Number ofsubjects: 239 120 643 Baseline 148 420 208 OLE src=https:reader034vdocumentsnetreader034viewer20220421205e99f1c14672c770645f32dfhtml5thumbnails26jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 27button div class=ts-image amp-img class=ts-thumb alt=Page 27: · SOC IECAS evolocumab E o 232 632 283 OLE 234 116 624 232 OLE 440 438 212 OLE 153 434 213 -10 -20 -30 -50 -60 -70 _80 Number ofsubjects: 239 120 643 Baseline 148 420 208 OLE src=https:reader034vdocumentsnetreader034viewer20220421205e99f1c14672c770645f32dfhtml5thumbnails27jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 28button div class=ts-image amp-img class=ts-thumb alt=Page 28: · SOC IECAS evolocumab E o 232 632 283 OLE 234 116 624 232 OLE 440 438 212 OLE 153 434 213 -10 -20 -30 -50 -60 -70 _80 Number ofsubjects: 239 120 643 Baseline 148 420 208 OLE src=https:reader034vdocumentsnetreader034viewer20220421205e99f1c14672c770645f32dfhtml5thumbnails28jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 29button div class=ts-image amp-img class=ts-thumb alt=Page 29: · SOC IECAS evolocumab E o 232 632 283 OLE 234 116 624 232 OLE 440 438 212 OLE 153 434 213 -10 -20 -30 -50 -60 -70 _80 Number ofsubjects: 239 120 643 Baseline 148 420 208 OLE src=https:reader034vdocumentsnetreader034viewer20220421205e99f1c14672c770645f32dfhtml5thumbnails29jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 30button div class=ts-image amp-img class=ts-thumb alt=Page 30: · SOC IECAS evolocumab E o 232 632 283 OLE 234 116 624 232 OLE 440 438 212 OLE 153 434 213 -10 -20 -30 -50 -60 -70 _80 Number ofsubjects: 239 120 643 Baseline 148 420 208 OLE src=https:reader034vdocumentsnetreader034viewer20220421205e99f1c14672c770645f32dfhtml5thumbnails30jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 31button div class=ts-image amp-img class=ts-thumb alt=Page 31: · SOC IECAS evolocumab E o 232 632 283 OLE 234 116 624 232 OLE 440 438 212 OLE 153 434 213 -10 -20 -30 -50 -60 -70 _80 Number ofsubjects: 239 120 643 Baseline 148 420 208 OLE src=https:reader034vdocumentsnetreader034viewer20220421205e99f1c14672c770645f32dfhtml5thumbnails31jpg width=142 height=106 layout=responsive amp-img divdiv